embalaje : 1mLx10mM(inDMSO)
Synonyms: LY-110140
| Description | Fluoxetine (LY-110140) is a highly specific serotonin uptake inhibitor and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor. Fluoxetine has antidepressant activity. |
| Targets & IC50 | JAR cells:32.4 nM, MDA-MB-436 cells:0.5 μM, CHO cells:13.1 μM, HEK293 cells:1020 nM, MDA-MB-231 cells:0.5 μM, Ventricular myocyte cells:2.82 μM, HeLa cells:10 μM |
| In vitro | METHODS: Mouse cortical near-pure neuronal cell cultures were treated with Fluoxetine (3-30 µM) for 24 h. Cell viability was measured by MTT assay. RESULTS: Fluoxetine induced neuronal death in a concentration-dependent manner. [1] METHODS: Human gastric cancer cells AGS were treated with Fluoxetine (10-20 µM) for 24 h. Apoptosis was detected by Flow cytometry. RESULTS: The number of early apoptotic cells in Fluoxetine-treated group was significantly increased by about 4-fold and 10-fold, respectively. [2] |
| In vivo | METHODS: To assay antidepressant activity in vivo, Fluoxetine (2.5-10 mg/kg) was administered intraperitoneally to MRL/MpJ mice twice daily for twenty-six days. RESULTS: Chronic treatment with 5 and 10 mg/kg Fluoxetine significantly increased cell proliferation and BDNF levels in the hippocampus. Only chronic treatment with the highest Fluoxetine increased BDNF levels in the frontal cortex. [3] METHODS: To test antidepressant activity in vivo, Fluoxetine (18 mg/kg) was administered orally once daily for three weeks to a model of corticosterone-induced anxiety/depression-like behavior in C57BL/6Ntac mice. RESULTS: Chronic Fluoxetine treatment reversed the anxiety phenotype. Regarding total distance traveled, chronic corticosterone treatment showed a nonsignificant trend that was eliminated by chronic Fluoxetine treatment. [4] |
| Synonyms | LY-110140 |
| Molecular Weight | 309.33 |
| Formula | C17H18F3NO |
| Cas No. | 54910-89-3 |
| Smiles | CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |
| Relative Density. | 1.159 g/cm3 |
| Storage | Keep away from direct sunlight Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 237.5 mg/mL (767.79 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 5% DMSO+95% Saline: 0.3 mg/mL (0.97 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
